BPTS News and Press, Biophytis SA From 12/01/22

Following the positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in the treatment of pneumonia in COVID-19 patients at risk of repiratory failure, Biophytis management is inviting all of Biophytis' stakeholders to an onl...

Biophytis ( NASDAQ: BPTS ) said its medicine Sarconeos help cut the risk of early death or respiratory failure in patients with COVID-19 in a post-hoc analysis of a phase 2-3 trial. The company had reported data from this phase 2-3 study , dubbed COVA, in Septem...

A reduction in the risk of early death or respiratory failure at day 28 of 45% in the Intent-To-Treat (ITT) population and 53% in the Per Protocol (PP) population A reduction in the risk of death at day 90 of 43% in the ITT population and 70% in the PP population The start of regu...

PARIS, FRANCE and CAMBRIDGE, MASSACHUSETTS / ACCESSWIRE / October 31, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associat...

PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / October 26, 2022 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with agi...

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 15, 2022 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with...

On July 16th July 2021, the Paris Court had imposed on Biophytis a penalty payment of EUR 1,500,000 in favour of Negma Group Ltd, following a judgment of the Paris Commercial Court On September 8th 2022, the Paris Court of Appeal partially reversed the judgment of the Enforcement Judge...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com It’s time for another look at the biggest pre-market stock movers as we see why shares are moving Wednesday morning! Moving stocks this morning are earnings reports, cli...

Biophytis ( NASDAQ: BPTS ) said its drug Sarconeos was better at reducing the risk of respiratory failure or early death in patients with COVID-19,compared to placebo. The phase 2-3 study, dubbed COVA, evaluated Sarconeos  (BIO101) against placeb...

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 7th, 2022 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated wit...